ロザイ・ドルフマン病市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別（古典的ロザイ・ドルフマン病、節外ロザイ・ドルフマン病）、手技タイプ別、エンドユーザー別、地域別、競合別、2020-2030F

世界のロザイ・ドルフマン病（RDD）市場は、2024年に6億4,705万米ドルと評価され、2030年には9億6,266万米ドルに達すると予測され、予測期間中に6.82％の複合年間成長率（CAGR）で拡大すると予測されています。

同市場はヘルスケア産業における専門的かつ重要なセグメントであり、大量のリンパ節腫脹を伴う類洞組織球症（SHML）としても知られる稀な非悪性疾患の診断、治療、進行中の調査に焦点を当てています。

RDDは、主にリンパ節内で組織球（白血球の一種）が過剰に増殖・蓄積することを特徴とするが、他の組織や臓器に影響を及ぼすこともあります。まれな疾患であるにもかかわらず、世界の認知度の高まり、診断技術の進歩、効果的な治療戦略の追求により、市場の成長は加速しています。

主な促進要因

罹患率の上昇と診断技術の進歩

ロザイ・ドルフマン病は、推定有病率が20万人に1人、米国では年間約100人の新規症例が報告されるなど、依然としてまれな疾患であるが、診断能力の向上により、世界的に疾患の特定が増加しています。画像診断技術、病理組織学、分子診断学における革新は、RDD診断の正確性と迅速性を向上させ、報告症例数の増加に寄与し、標的治療介入に対する需要を促進しています。

このような認識の高まりは、特殊な診断ツールや治療法の開発を目指した研究開発に拍車をかけています。一部のRDD患者におけるBRAF-V600Eなどの遺伝子変異の同定を含む最近の発見は、精密医療と個別化治療戦略の新たな機会を開いた。その結果、製薬会社やヘルスケアプロバイダーは、RDDの臨床的・生物学的特徴に特化した治療法に投資しています。

この市場には、診断アッセイ、画像システム、医薬品、支持療法ソリューションなど、幅広い製品があります。製薬企業、学術機関、臨床プロバイダーの協力体制は、研究を進め、疾患メカニズムを解明し、潜在的なバイオマーカーを探索し、革新的な治療法を開発する上で極めて重要です。

主な課題

疾患有病率の低さと認知度の低さ

市場開拓の大きな障壁は、RDDの有病率が極めて低く、さらに医療従事者の認知度が低いことです。RDDは稀な疾患であるため、臨床症状が他の一般的な疾患と類似している可能性があり、誤診や診断の遅れにつながることが多いです。RDDは、無症候性のリンパ節腫大から広範な臓器病変まで、幅広い症状を呈することがあり、適時の発見をさらに複雑にしています。

RDDに臨床的に遭遇する頻度が低いため、医師の間でも一般的になじみが薄く、迅速かつ正確な診断が妨げられています。さらに、広く認識されていないことが、RDDに特化した研究への資金援助や投資に影響し、診断や治療法の革新の進歩を制限しています。このような投資不足は、効果的で的を絞った介入の開発に課題をもたらし、この疾患の病態生理学の幅広い理解を妨げています。

主要市場動向

免疫組織化学と分子プロファイリングの採用

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のロザイ・ドルフマン病市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 病型別（古典的（節性）ローザイ・ドルフマン病、節外性ローザイ・ドルフマン病）
  • 処置の種類別（診断、治療）
  • エンドユーザー別（病院・診療所、外来診療センター、その他）
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米のロザイ・ドルフマン病市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州のロザイ・ドルフマン病市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域のロザイ・ドルフマン病市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のロザイ・ドルフマン病市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのロザイ・ドルフマン病市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 PESTEL分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Koninklijke Philips N.V.
• GE HealthCare
• Canon Inc
• Siemens Healthineers
• SternMed GmbH
• Jubilant Cadista Pharmaceuticals Inc
• LGM Pharma
• Henan Lihua Pharmaceutical Co., Ltd
• Niksan Pharmaceutical
• Sandoz Canada Inc

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Rosai-Dorfman Disease (RDD) market was valued at USD 647.05 million in 2024 and is projected to reach USD 962.66 million by 2030, expanding at a compound annual growth rate (CAGR) of 6.82% over the forecast period. This market represents a specialized yet vital segment of the healthcare industry, focusing on the diagnosis, treatment, and ongoing research of Rosai-Dorfman Disease-a rare, non-malignant disorder also known as sinus histiocytosis with massive lymphadenopathy (SHML).

RDD is characterized by the excessive proliferation and accumulation of histiocytes-a type of white blood cell-primarily within lymph nodes, though it may also affect other tissues and organs. Despite its rarity, growing global awareness, advancements in diagnostic technologies, and the pursuit of effective treatment strategies have accelerated market growth.

Key Drivers

Rising Incidence and Diagnostic Advancements

While Rosai-Dorfman Disease remains an uncommon condition-with an estimated prevalence of 1 in 200,000 individuals and approximately 100 new cases reported annually in the United States-enhanced diagnostic capabilities have led to increased identification of the disease globally. Innovations in imaging techniques, histopathology, and molecular diagnostics have improved the accuracy and timeliness of RDD diagnoses, contributing to a higher reported case volume and driving demand for targeted therapeutic interventions.

This growing recognition has fueled research and development activities aimed at creating specialized diagnostic tools and treatments. Recent discoveries, including the identification of genetic mutations such as BRAF-V600E in select RDD patients, have opened new opportunities for precision medicine and personalized treatment strategies. As a result, pharmaceutical firms and healthcare providers are investing in therapies tailored specifically to the clinical and biological characteristics of RDD.

The market spans a broad range of offerings including diagnostic assays, imaging systems, pharmaceuticals, and supportive care solutions. Collaborative efforts among pharmaceutical companies, academic institutions, and clinical providers are crucial in advancing research, uncovering disease mechanisms, exploring potential biomarkers, and developing innovative treatments.

Key Challenges

Low Disease Prevalence and Limited Awareness

A significant barrier to market development is the exceptionally low prevalence of RDD, compounded by limited awareness among healthcare professionals. The rarity of the condition often leads to misdiagnosis or delayed diagnosis, as its clinical presentation may mimic other, more common diseases. RDD can manifest with a wide spectrum of symptoms, from asymptomatic lymph node enlargement to extensive organ involvement, further complicating timely detection.

Infrequent clinical encounters with RDD contribute to a general unfamiliarity among physicians, hindering prompt and accurate diagnosis. Additionally, the lack of widespread awareness impacts funding and investment in RDD-specific research, limiting advancements in diagnostic and therapeutic innovations. This underinvestment challenges the development of effective, targeted interventions and impedes the broader understanding of the disease's pathophysiology.

Key Market Trends

Adoption of Immunohistochemistry and Molecular Profiling

The market is witnessing a paradigm shift toward precision diagnostics, underscored by the increasing use of immunohistochemistry (IHC) and molecular profiling. These technologies are becoming standard in identifying and confirming RDD cases with greater accuracy. IHC techniques enable the detection of disease-specific protein markers such as S100 and CD68, facilitating differentiation from other histiocytic and lymphoproliferative disorders.

Simultaneously, molecular profiling-through platforms such as next-generation sequencing (NGS)-is uncovering recurrent mutations (e.g., KRAS, MAP2K1) associated with RDD pathogenesis. These insights are paving the way for personalized therapeutic approaches, particularly for patients with refractory or recurrent disease.

As molecular diagnostic tools become more accessible and cost-effective, their adoption is expanding across both developed and emerging healthcare markets. Institutions are integrating these technologies into clinical practice, not only improving diagnostic precision but also enhancing patient monitoring and prognosis assessment.

Key Market Players

• Koninklijke Philips N.V.
• GE HealthCare
• Canon Inc
• Siemens Healthineers
• SternMed GmbH
• Jubilant Cadista Pharmaceuticals Inc
• LGM Pharma
• Henan Lihua Pharmaceutical Co., Ltd
• Niksan Pharmaceutical
• Sandoz Canada Inc

Report Scope:

In this report, the Global Rosai-Dorfman Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Rosai-Dorfman Disease Market, By Type:

• Classic (nodal) Rosai-Dorfman disease
• Extranodal Rosai-Dorfman disease

Global Rosai-Dorfman Disease Market, By Route of Administration:

• Oral
• Parenteral
• Sublingual
• Nasal

Global Rosai-Dorfman Disease Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centres
• Others

Global Rosai-Dorfman Disease Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Rosai-Dorfman Disease Market.

Available Customizations:

Global Rosai-Dorfman Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Rosai-Dorfman Disease Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Classic (nodal) Rosai-Dorfman disease, Extranodal Rosai-Dorfman disease)
  • 5.2.2. By Procedure Type (Diagnosis, Treatment)
  • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centres, Others)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Rosai-Dorfman Disease Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Procedure Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Rosai-Dorfman Disease Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Procedure Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Mexico Rosai-Dorfman Disease Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Procedure Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Canada Rosai-Dorfman Disease Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Procedure Type
      • 6.3.3.2.3. By End User

7. Europe Rosai-Dorfman Disease Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Procedure Type
  • 7.2.3. By End User
  • 7.2.4. By Age Group
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Rosai-Dorfman Disease Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Procedure Type
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Rosai-Dorfman Disease Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Procedure Type
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Rosai-Dorfman Disease Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Procedure Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Rosai-Dorfman Disease Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Procedure Type
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Rosai-Dorfman Disease Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Procedure Type
      • 7.3.5.2.3. By End User

8. Asia-Pacific Rosai-Dorfman Disease Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Procedure Type
  • 8.2.3. By End User
  • 8.2.4. By Age Group
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Rosai-Dorfman Disease Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Procedure Type
      • 8.3.1.2.3. By End User
  • 8.3.2. India Rosai-Dorfman Disease Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Procedure Type
      • 8.3.2.2.3. By End User
  • 8.3.3. South Korea Rosai-Dorfman Disease Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Procedure Type
      • 8.3.3.2.3. By End User
  • 8.3.4. Japan Rosai-Dorfman Disease Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Procedure Type
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Rosai-Dorfman Disease Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Procedure Type
      • 8.3.5.2.3. By End User

9. South America Rosai-Dorfman Disease Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Procedure Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Rosai-Dorfman Disease Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Procedure Type
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Rosai-Dorfman Disease Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Procedure Type
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Rosai-Dorfman Disease Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Procedure Type
      • 9.3.3.2.3. By End User

10. Middle East and Africa Rosai-Dorfman Disease Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Procedure Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Rosai-Dorfman Disease Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Procedure Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Rosai-Dorfman Disease Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Procedure Type
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Rosai-Dorfman Disease Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Procedure Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Koninklijke Philips N.V.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. GE HealthCare
• 15.3. Canon Inc
• 15.4. Siemens Healthineers
• 15.5. SternMed GmbH
• 15.6. Jubilant Cadista Pharmaceuticals Inc
• 15.7. LGM Pharma
• 15.8. Henan Lihua Pharmaceutical Co., Ltd
• 15.9. Niksan Pharmaceutical
• 15.10. Sandoz Canada Inc

16. Strategic Recommendations

17. About Us & Disclaimer